Tarsus Pharmaceuticals (TARS) PT Raised to $63 at BofA Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Tarsus Pharmaceuticals (TARS) PT Raised to $60 at Barclays
May 10, 2024 3:29 AM EDTBarclays analyst Balaji Prasad raised the price target on Tarsus Pharmaceuticals (NASDAQ: TARS) to $60.00 (from $50.00) while maintaining a Overweight rating.... More
Tarsus Pharmaceuticals (TARS) PT Raised to $61 at Oppenheimer
May 9, 2024 7:36 AM EDTOppenheimer analyst Francois Brisebois raised the price target on Tarsus Pharmaceuticals (NASDAQ: TARS) to $61.00 (from $59.00) while maintaining a Outperform rating.... More
Tarsus Pharmaceuticals, Inc. (TARS) Tops Q1 EPS by 17c
May 8, 2024 5:13 PM EDTTarsus Pharmaceuticals, Inc. (NASDAQ: TARS) reported Q1 EPS of ($1.01), $0.17 better than the analyst estimate of ($1.18). Revenue for the quarter came in at $27.61 million versus the consensus estimate of $17.5 million.
For earnings history and earnings-related data on Tarsus Pharmaceuticals, Inc. (TARS) click here.
... More